Clinical and Pathologic Predictors of Outcome in Thymoma-Associated Myasthenia Gravis

Annals of Thoracic Surgery

Volumn 76, Issue 5, 2003, Pages 1643-1649

  López Cano, Manuel ^a   Ponseti Bosch, José M ^a   Espin Basany, Eloi ^a   Sánchez García, José L ^a   Armengol Carrasco, Manuel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CELL DIFFERENTIATION; CHILD; CLINICAL FEATURE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; MYASTHENIA GRAVIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURGICAL MORTALITY; SYMPTOM; THYMECTOMY; THYMOMA; TREATMENT OUTCOME;

EID: 17144435704     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)01139-1     Document Type: Article

References (31)

1. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-810.
2. Osserman KE, Genkins G. Studies in myasthenia gravis: review of twenty-year experience in over 1200 patients. Mt Sinai J Med 1971;38:497-537.
3. Bernatz PE, Harrison EG, Clagett OT. Thymoma: a clinicopathologic study. J Thorac Cardiovasc Surg 1961;42:424-44.
4. Marino M, Müller-Hermelink HK. Thymoma and thymic carcinoma: relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch Pathol Anat 1985;407:119-49.
5. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-93.
6. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995;60:908-14.
7. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999;230:562-74.
8. Li Z, Cui Y, Zhang Z, Ji Z, Fei L, Liu W. Analysis of thymoma excision in patients with myasthenia gravis. Chin Med J Engl 1996;109:946-8.
9. Busch C, Machens A, Pichlmeier U, Emskötter T, Izbicki JR. Long-term outcome and quality of life after thymectomy for myasthenia gravis. Ann Surg 1996;224:225-32.
10. Pandit L, Rao SN. Thymomatous myasthenia gravis. J Assoc Physicians India 1995;43:543-5.
11. Osserman KE. Myasthenia gravis. New York: Grune-Stratton, 1958:79-80.
12. Monden Y, Uyama T, Nakahara K, et al. Clinical characteristics and prognosis of myasthenia gravis with other autoimmune diseases. Ann Thorac Surg 1986;41:189-92.
13. Monden Y, Nakahara K, Kagotani K, Fujii Y, Masaoka A, Kawashima Y. Myasthenia gravis with thymoma: analysis of and postoperative prognosis for 65 patients with thymomatous myasthenia gravis. Ann Thorac Surg 1984;38:46-52.
14. Gerein AN, Srivastava SP, Burgess J. Thymoma: a ten year review. Am J Surg 1978;136:49-53.
15. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 1990; 28:312-9.
16. Weisbrod GL, Herman SJ. Mediastinal masses: diagnosis with non-invasive techniques. Semin Thorac Cardiovasc Surg 1992;4:3-22.
17. Gajdos P, Outin H, Elkaharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1: 406-7.
18. Ibars IB, Ponseti J, Español T, Matias-Guiu J, CodinaPuiggros A. High-dose intravenous gamma-globulin therapy for myasthenia gravis. J Neurol 1987;234:363.
19. Masaoka A, Nagaoka Y, Kotake Y. Distribution of thymic tissue at the anterior mediastinum. J Thorac Cardiovasc Surg 1975;70:747-54.
20. Jaretzki A III, Penn AS, Younger DS, et al. "Maximal" thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg 1988;95:747-57.
21. Jaretzki A III, Wolff M. "Maximal" thymectomy for myasthenia gravis. Surgical anatomy and operative technique. J Thorac Cardiovasc Surg 1988;96:711-6.
22. Müller-Hermelink HK, Marx A, Geuder AM, Kirchner T. The pathological basis of thymoma-associated myasthenia gravis. Ann NY Acad Sci 1993;681:56-65.
23. Ho FC, Fu KH, Lam SY, Chiu SW, Chan AC, Müller-Hermelink HK. Evaluation of a histogenetic classification for thymic epithelial tumours. Histopathology 1994;25:21-9.
24. Pescarmona E, Rendina EA, Venuta F, et al. Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 1990;50:534-8.
25. Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Müller-Hermelink HK. Pathogenesis of myasthenia gravis. Virchows Arch 1997;430:355-64.
26. Müller-Hermelink HK, Marx A. Pathological aspects of malignant and benign thymic disorders. Ann Med 1999; 31(Suppl 2):5-14.
27. Lardinois D, Rechsteiner R, Lang RH, et al. Prognostic relevance of Masaoka and Müller-Hermelink classification in patients with thymic tumors. Ann Thorac Surg 2000;69: 1550-5.
28. Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol 1999;17:2280-9.
29. Lara PN Jr. Malignant thymoma: current status and future directions. Cancer Treat Rev 2000;26:127-31.
30. Marx A, Müller-Hermelink HK. From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. The Second Conference on Biological and Clinical Aspects of Thymic Epithelial Tumors and related recent developments [editorial]. Pathol Res Pract 1999;195:515-33.
31. Kou TT. Classification of thymic epithelial neoplasms: a controversial issue coming to an end? J Cell Mol Med 2001;5:442-148.